Cancer

Prescription drugs are currently on the market that are known to cause or promote the growth of cancerous cells. It is doubtful that patients would choose to ingest these medications if they were informed of the risk of malignance's. Inconceivably the FDA has allowed these products to remain on the market, especially when it is well accepted that patients and their physicians are terribly uninformed when it comes to the risks associated with prescription drugs and that Big Pharma has mastered the art of minimizing risk information in an effort to sell products with unfavorable side effects, including cancer.

Combination hormone replacement therapy drugs, such as Prempro, Premarin, and Provera, have been noted in multiple studies to promote the growth of breast cancer in post-menopausal women. Once this risk information was uncovered and disclosed to patients, prescriptions for HRT dropped dramatically, and the rates of breast cancer also fell precipitously. Unfortunately, however, manufacturers such as Wyeth and Pfizer, were able to sell these drugs for decades to women who were oversold on the benefits and terribly misled as to the risks.

Actos, which is also known as pioglitazone, is another drug that the FDA permitted to remain on the market Takeda Pharmaceutical continued to aggressively sell despite findings linking Actos to cancer. Actos is a popular diabetes drug in the same class as Rezulin (recalled due to liver failure) and Avandia (essentially withdrawn from the market due to links to heart attacks, congestive heart failure, and strokes). Many patients took all three of these beleaguered drugs, and were encouraged to do so by full-page newspaper advertisements and other marketing efforts by Takeda heralding Actos as a much safer alternative to Rezulin and Avandia.